ReviewMedComm2026
De Novo Synthesis in Cancer Immunotherapy: Applications and Prospects.
Review in MedComm, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
De novo protein design enables the creation of proteins with entirely novel structures and biological functions from scratch, offering a promising new paradigm for cancer immunotherapy. Emerging methodologies are integrating principles of rational design, including specificity, modularity, and adaptability, into the development process from the outset. This innovative strategy holds the potential to advance how people understand and intervene against malignancy, through the strategic utilization of immune checkpoint regulation, cytokine engineering, cellular therapy, and signaling pathway remodeling, with each approach demonstrating distinct mechanisms to augment antitumor immune responses. To further optimize these strategies, advanced computational tools and synthetic biology techniques are now being actively deployed to rationally design immune-modulatory proteins for enhanced cytokine engineering, and to significantly enhance the efficacy of cellular immunotherapies through precision-engineered chimeric antigen receptor T-cell immunotherapy constructs and bispecific antibodies, collectively addressing the key limitations of current therapeutic approaches. To this end, this review discusses how the latest advances in these techniques can deepen our understanding of the usage of
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.